Fate Therapeutics Details Off-the-Shelf CAR T Progress in Lupus and Solid Tumors at Needham Conference

Fate Therapeutics (NASDAQ: FATE) used a presentation at the Needham Healthcare Conference to outline its strategy for developing "off-the-shelf" CAR T-cell therapies, highlighting clinical progress in autoimmune disease with FT819 and early proof-of-concept signals in solid tumors with FT836. President and CEO Bob Valamehr was joined by Chief Financial Officer Kamal Adawi. Positioning CAR T as